Skip to main content

Pimavanserin Side Effects

Medically reviewed by Drugs.com. Last updated on Nov 15, 2023.

Applies to pimavanserin: oral capsule, oral tablet.

Warning

Oral route (Tablet)

Increased Mortality in Elder Patients With Dementia Related PsychosisElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Pimavanserin is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease.

Serious side effects of Pimavanserin

Along with its needed effects, pimavanserin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pimavanserin:

Incidence not known

Other side effects of Pimavanserin

Some side effects of pimavanserin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to pimavanserin: oral capsule, oral tablet.

General

The most commonly reported side effects are peripheral edema and confusional state.[Ref]

Gastrointestinal

Common (1% to 10%): Constipation, nausea

Postmarketing reports: Tongue swelling[Ref]

Psychiatric

Hallucinations included visual, auditory, tactile, and somatic hallucinations.[Ref]

Common (1% to 10%): Confusional state, hallucinations[Ref]

Cardiovascular

Common (1% to 10%): Peripheral edema

Frequency not reported: QT interval prolongation[Ref]

Nervous system

Common (1% to 10%): Gait disturbance[Ref]

Other

Common (1% to 10%): Fatigue[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Dermatologic

Postmarketing reports: Circumoral edema, rash, urticaria[Ref]

Hypersensitivity

Postmarketing reports: Angioedema[Ref]

Respiratory

Postmarketing reports: Dyspnea, throat tightness[Ref]

References

1. Product Information. Nuplazid (pimavanserin). Accelis Pharma. 2016.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.